Literature DB >> 25384360

Extralevator versus standard abdominoperineal excision for rectal cancer.

S K Perdawood1, T Lund.   

Abstract

BACKGROUND: Extralevator abdominoperineal excision (ELAPE) probably improves the oncological quality of low rectal cancer surgery, as compared to standard abdominoperineal excision (SAPE), possibly due to lower rates of accidental perioperative bowel perforations and lower rates of circumferential resection margin (CRM) positivity. The procedure may however, increase post-operative morbidity. The aim of this paper was to compare outcomes of SAPE and ELAPE for carcinoma of the lower rectum.
METHODS: This is a retrospective study of patients operated on at a single colorectal unit, in a provincial hospital in Denmark. Consecutive patients undergoing abdominoperineal excision (APE) between 2006 and 2012 were included. During this period, a gradual paradigm shift occurred towards adopting ELAPE, although both procedures were performed without a clear selection strategy. We reviewed medical records, including the pathological and radiological data. Patients were divided into two groups, SAPE and ELAPE. Main endpoints were rates of positive CRM, intraoperative bowel perforations, local recurrence rate, length of hospital stay, operative time, and perineal wound-related complications.
RESULTS: One hundred and seven patients were included (median age 68 years, range 42-88 years; men = 72). The SAPE group included 39 patients and the ELAPE group 68 patients. Intraoperative bowel perforation was significantly lower in the ELAPE group (20.5% SAPE vs 7.4% ELAPE, p = 0.045). The rate of positive CRM was not significantly different (2.6% SAPE vs 7.4% ELAPE, p = 0.413). The local recurrence rate was not statistically significant (17.9% SAPE vs 13.2% ELAPE, p = 0.513). In the ELAPE group, operative time and hospital stay were significantly longer than the SAPE group (p = 0.001 and p = 0.021, respectively).
CONCLUSIONS: We found low rates of positive CRM after APE compared with the literature. ELAPE did not reduce these rates, and although the local recurrence rate was lower, this did not reach statistical significance. ELAPE has significantly reduced the rate of intraoperative bowel perforation and can optimize low rectal cancer surgery in selected patients. We found no significant differences between the two procedures regarding wound-related complications. A tailored approach and a larger trial with longer follow-up are needed to evaluate long-term results.

Entities:  

Mesh:

Year:  2014        PMID: 25384360     DOI: 10.1007/s10151-014-1243-8

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  38 in total

1.  The multidisciplinary team conference in rectal cancer--a step forward.

Authors:  P Wille-Jørgensen; S Bülow
Journal:  Colorectal Dis       Date:  2009-03       Impact factor: 3.788

2.  Sites of surgical wasting in the abdominoperineal specimen.

Authors:  G Salerno; I Chandler; A Wotherspoon; K Thomas; B Moran; G Brown
Journal:  Br J Surg       Date:  2008-09       Impact factor: 6.939

3.  Abdominoperineal excision of the rectum--an endangered operation. Norman Nigro Lectureship.

Authors:  R J Heald; R K Smedh; A Kald; R Sexton; B J Moran
Journal:  Dis Colon Rectum       Date:  1997-07       Impact factor: 4.585

4.  Prone or lithotomy positioning during an abdominoperineal resection for rectal cancer results in comparable oncologic outcomes.

Authors:  Luiz Felipe de Campos-Lobato; Luca Stocchi; David W Dietz; Ian C Lavery; Victor W Fazio; Matthew F Kalady
Journal:  Dis Colon Rectum       Date:  2011-08       Impact factor: 4.585

5.  Short-term outcome after gluteus maximus myocutaneous flap reconstruction of the pelvic floor following extra-levator abdominoperineal excision of the rectum.

Authors:  C Anderin; A Martling; J Lagergren; A Ljung; T Holm
Journal:  Colorectal Dis       Date:  2012-09       Impact factor: 3.788

6.  Inadvertent perforation of the rectum during abdominoperineal resection.

Authors:  G A Porter; G E O'Keefe; W W Yakimets
Journal:  Am J Surg       Date:  1996-10       Impact factor: 2.565

7.  Favorable pathologic and long-term outcomes from the conventional approach to abdominoperineal resection.

Authors:  David E Messenger; Zane Cohen; Richard Kirsch; Brenda I O'Connor; J Charles Victor; Harden Huang; Robin S McLeod
Journal:  Dis Colon Rectum       Date:  2011-07       Impact factor: 4.585

8.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

Review 9.  Controversies in abdominoperineal excision.

Authors:  Torbjörn Holm
Journal:  Surg Oncol Clin N Am       Date:  2014-01       Impact factor: 3.495

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  13 in total

1.  Extralevator Abdominal Perineal Excision Versus Standard Abdominal Perineal Excision: Impact on Quality of the Resected Specimen and Postoperative Morbidity.

Authors:  Angelita Habr-Gama; Guilherme P São Julião; Adrian Mattacheo; Luiz Felipe de Campos-Lobato; Edgar Aleman; Bruna B Vailati; Joaquim Gama-Rodrigues; Rodrigo Oliva Perez
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

2.  Long-term outcome of extralevator abdominoperineal excision (ELAPE) for low rectal cancer.

Authors:  Sigmar Stelzner; Gunter Hellmich; Anja Sims; Thomas Kittner; Eric Puffer; Joerg Zimmer; Dorothea Bleyl; Helmut Witzigmann
Journal:  Int J Colorectal Dis       Date:  2016-09-09       Impact factor: 2.571

3.  Laparoscopic translevator approach to abdominoperineal resection for rectal adenocarcinoma: feasibility and short-term oncologic outcomes.

Authors:  Vanessa N Palter; Steven MacLellan; Shady Ashamalla
Journal:  Surg Endosc       Date:  2015-10-20       Impact factor: 4.584

4.  Outcome of extralevator abdominoperineal excision over conventional abdominoperineal excision for low rectal tumor: a meta-analysis.

Authors:  Yue Yang; Huirong Xu; Zhenhua Shang; Shouzhen Chen; Fan Chen; Qiming Deng; Li Luo; Liang Zhu; Benkang Shi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Extralevator versus standard abdominoperineal excision in locally advanced rectal cancer: a retrospective study with long-term follow-up.

Authors:  Anu Carpelan; J Karvonen; P Varpe; A Rantala; A Kaljonen; J Grönroos; H Huhtinen
Journal:  Int J Colorectal Dis       Date:  2018-02-14       Impact factor: 2.571

6.  Extralevator abdominoperineal excision for rectal cancer with biological mesh for pelvic floor reconstruction.

Authors:  Wei Ge; Song-Song Jiang; Wang Qi; Hao Chen; Li-Ming Zheng; Gang Chen
Journal:  Oncotarget       Date:  2017-01-31

7.  Oncological outcomes of abdominoperineal resection for the treatment of low rectal cancer: A retrospective review of a single UK tertiary centre experience.

Authors:  Anwar Hussain; Fahad Mahmood; Andrew D W Torrance; Helen Clarke; Cordelia Howitt; Robin Dawson
Journal:  Ann Med Surg (Lond)       Date:  2018-06-26

8.  Sparing Sphincters and Laparoscopic Resection Improve Survival by Optimizing the Circumferential Resection Margin in Rectal Cancer Patients.

Authors:  Metin Keskin; Adem Bayraktar; Emre Sivirikoz; Gülcin Yegen; Bora Karip; Esra Saglam; Mehmet Türker Bulut; Emre Balik
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

9.  Standard versus extralevator abdominoperineal excision and oncologic outcomes for patients with distal rectal cancer: A meta-analysis.

Authors:  Yunfeng Zhang; Duo Wang; Lizhe Zhu; Bin Wang; Xiaoxia Ma; Bohui Shi; Yu Yan; Can Zhou
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

10.  Extralevator abdominoperineal excision versus abdominoperineal excision for low rectal cancer: a meta-analysis.

Authors:  Xin-Yu Qi; Ming Cui; Mao-Xing Liu; Kai Xu; Fei Tan; Zhen-Dan Yao; Nan Zhang; Hong Yang; Cheng-Hai Zhang; Jia-Di Xing; Xiang-Qian Su
Journal:  Chin Med J (Engl)       Date:  2019-10-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.